Table 3.
Substance use history of 154 participants undergoing treatment for cannabis use in New South Wales, Australia
| Substance use | Total (N = 154) | SCRAs (n = 82) | Cannabis (n = 72) |
Comparison of lifetime substance usea (p-value) |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ever (%) |
3 month (%) |
1 month (%) |
Median Days/28 n (IQR) |
Ever (%) |
3 month (%) |
1 month (%) |
Median Days/28 n (IQR) |
Ever (%) |
3 month (%) |
1 month (%) |
Median Days/28 n (IQR) |
||
| Cannabis | 100.0 | 92.2 | 84.4 | 26 (18–28) | 100.0 | 90.2 | 81.7 | 21 (4.5–26) | 100.0 | 94.4 | 87.5 | 28 (14–28) | - |
| SCRA | 53.2 | 14.3 | 10.4 | 20 (1–28) | 100.0 | 26.8 | 19.5 | 20 (1–28) | 0 | 0 | 0 | 0 | - |
| Alcohol | 96.1 | 72.1 | 63.6 | 5 (2–14) | 97.6 | 76.8 | 68.3 | 5 (2–13) | 94.4 | 66.7 | 58.3 | 5 (3–14) | 0.319 |
| Tobacco | 89.6 | 80.5 | 78.6 | 28 (26–28) | 90.2 | 82.9 | 79.3 | 28 (25–28) | 88.9 | 77.8 | 77.8 | 28 (28–28) | 0.783 |
| Amphetamines | 79.2 | 38.3 | 27.3 | 4 (1–20) | 80.5 | 35.4 | 26.8 | 5 (1–20) | 77.8 | 41.7 | 27.8 | 4 (1–11) | 0.679 |
| Ecstasy | 68.2 | 14.9 | 7.1 | 2 (1–2) | 72.0 | 18.3 | 7.3 | 1 (1–2) | 63.9 | 11.1 | 6.9 | 2 (1–2) | 0.284 |
| Hallucinogens | 53.9 | 3.9 | 1.9 | 3 (2–4) | 69.5 | 4.9 | 2.4 | 3 (2–3) | 36.1 | 2.8 | 1.4 | 3 (3–3) | < 0.001 |
| Cocaine | 51.9 | 11.0 | 5.8 | 2 (2–4) | 50.0 | 7.3 | 2.4 | 3 (3–6) | 54.2 | 15.3 | 9.7 | 2 (2–5) | 0.606 |
| Benzodiazepines—prescribed | 39.6 | 24.7 | 22.1 | 3 (2–7) | 45.1 | 29.3 | 26.8 | 3 (2–6) | 33.3 | 19.4 | 16.7 | 5 (2–7) | 0.136 |
| Opioids—prescribed | 36.4 | 23.4 | 18.8 | 7 (4–28) | 26.8 | 13.4 | 9.8 | 5 (2–15) | 47.2 | 34.7 | 29.2 | 10 (5–28) | 0.009 |
| Opioids—illicit | 28.6 | 8.4 | 7.1 | 2 (1–8) | 39.0 | 12.2 | 11.0 | 2 (1–7) | 16.7 | 4.2 | 2.8 | 17 (13–21) | 0.002 |
| Synthetic stimulants | 19.5 | 2.6 | 0 | 0 | 32.9 | 3.7 | 0 | 0 | 4.2 | 1.4 | 0 | 0 | < 0.001 |
| Benzodiazepines—illicit | 19.5 | 7.8 | 7.1 | 2 (1–4) | 25.6 | 12.2 | 11.0 | 2 (1–4) | 12.5 | 2.8 | 2.8 | 3 (3–3) | 0.040 |
| Inhalants | 16.9 | 0.6 | 0 | 0 | 26.8 | 0 | 0 | 0 | 5.6 | 1.4 | 0 | 0 | < 0.001 |
| Opioid agonist treatment | 7.1 | 2.7 | 2.7 | 28 (28–28) | 9.8 | 3.7 | 3.7 | 28 (28–28) | 4.2 | 1.4 | 1.4 | 28 (28–28) | 0.187 |
| Other | 6.5 | 0.6 | 0.6 | 1 (1–1) | 9.8 | 1.2 | 1.2 | 1 (1–1) | 2.8 | 0 | 0 | 0 | 0.080 |
aChi-square test comparisons of SCRA and cannabis groups for ever use of all substances, excluding cannabis and SCRAs